Metformin
The flagship "longevity drug" candidate — strong epidemiology in diabetics and pre-diabetics, big TAME RCT (Barzilai) still in progress as of 2026. | Compound
Aliases (5)
▸ Overview TL;DR
The flagship "longevity drug" candidate — strong epidemiology in diabetics and pre-diabetics, big TAME RCT (Barzilai) still in progress as of 2026. But it blunts skeletal-muscle adaptation to endurance exercise (Konopka 2019, Walton 2019), and a healthy 20yo with no metabolic dysfunction has nothing to fix. For Dylan: shelf it for now, reconsider at 35+ or if HOMA-IR drifts.
▸ Mechanism of action
Metformin is a small biguanide molecule that distributes preferentially into mitochondria of hepatocytes (and to a lesser extent muscle, gut, kidney) via the OCT1/OCT2/MATE transporters. Once inside, it does several things — the relative weight of each remains contested even after 70 years of clinical use.
1. Mitochondrial complex I partial inhibition (the primary thesis): Metformin partially and reversibly inhibits NADH:ubiquinone oxidoreductase (Complex I of the electron transport chain). This lowers ATP production locally → raises the AMP:ATP ratio → activates AMPK (the cellular energy-sensor kinase). AMPK then:
- Inhibits acetyl-CoA carboxylase (lowers fatty-acid synthesis)
- Inhibits mTORC1 (slows growth, induces autophagy)
- Activates fatty-acid oxidation
- Inhibits hepatic gluconeogenesis (the dominant clinical glucose-lowering effect)
2. Mitochondrial glycerophosphate dehydrogenase (mGPDH) inhibition (Madiraju thesis, 2014): Independent of AMPK, metformin inhibits mGPDH in liver, raising cytosolic NADH:NAD ratio and lowering glycerol-to-glucose conversion. This alternative explanation accounts for some of the glucose-lowering even in AMPK-knockout mice.
3. Gut effects (increasingly recognized): A large fraction of orally dosed metformin stays in the gut. It modifies the microbiome (increases Akkermansia muciniphila), increases GLP-1 secretion, and bile-acid recycling. Some of the metabolic benefit may be gut-mediated rather than hepatic.
4. Downstream "longevity" effects (the Barzilai/Blagosklonny case):
- mTOR inhibition → reduced cellular growth signaling → improved proteostasis
- AMPK activation → mitophagy + autophagy → cellular cleanup
- Improved insulin sensitivity → lower insulin → reduced IGF-1 axis activation
- Anti-inflammatory effects (mixed evidence)
- Possible direct anti-cancer effects (epidemiology suggests reduced cancer incidence in diabetics on metformin vs sulfonylureas)
▸ Pharmacokinetics No data
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸ Side effects + safety
- Common (>10% users): GI upset (nausea, bloating, loose stools, metallic taste) — usually transient, reduced by titration + extended-release + with-food dosing. ~20-30% experience some GI symptom in first month.
- Less common (1-10%): Vitamin B12 deficiency on chronic use (cumulative risk; clinically significant after 4-5 years; mechanism is reduced B12 absorption via altered ileal calcium-handling). Mild folate decrease. Slightly elevated homocysteine.
- Rare-serious (<1% but worth knowing):
- Lactic acidosis — historical concern inherited from phenformin (withdrawn 1977 for high lactic-acidosis rate). Metformin's risk is genuinely low (~3-9 cases per 100,000 patient-years) and almost always in renal insufficiency, severe hypoxia, or contrast-imaging settings. Hold metformin before contrast CT scans (standard practice).
- Hypoglycemia — rare as monotherapy in non-diabetics. Adds risk when combined with sulfonylureas/insulin.
- Specific watch periods: First 2-4 weeks for GI tolerability; annual B12 + homocysteine on chronic use; eGFR check before initiating + annually.
- Exercise-blunting (the under-appreciated risk for athletes): Mechanism-grounded and shown in two independent older-adult RCTs. Magnitude in young trained athletes is unstudied but extrapolated concern is real.
▸Interactions10 compounds
- berberine:SynergisticMechanistically overlapping (both AMPK activators). Stacking is redundant rather than additive. Pick one.
- GLP-1 agonists (semaglutide, tirzepatide):SynergisticStandard combination in T2D. Additive glycemic control. Different mechanisms.
- Vitamin B12 (mandatory for long-term users):SynergisticMethylcobalamin 1000mcg/day or hydroxocobalamin injections offset depletion. Non-negotiable on chronic metformin.
- Methylfolate / B6:SynergisticOffsets homocysteine elevation.
- Acarbose, SGLT2i (empagliflozin):SynergisticDifferent glycemic mechanisms; can stack.
- Rapamycin (theoretical longevity stack):SynergisticBoth inhibit mTOR via different routes. Some longevity practitioners stack low-dose metformin with weekly rapamycin. No human outcome data.
- Iodinated contrast (radiology):AvoidHold 48 hours pre/post for contrast CT due to lactic-acidosis risk via possible AKI.
- Heavy alcohol:AvoidIncreases lactic-acidosis risk via lactate buildup.
- Sulfonylureas / insulin without monitoring:AvoidHypoglycemia risk.
- High-intensity endurance training programs (the athlete concern):AvoidKonopka/Walton data shows blunted training adaptation. Not a "dangerous" interaction but a meaningful counterproductive one for performance athletes.
▸References8 sources
Bannister et al., 2014 — Diabetes Care: Can people with type 2 diabetes live longer than those without?
2014observational data sparking the TAME hypothesis
Diabetes Prevention Program Research Group, 2002 — NEJM: Reduction in incidence of type 2 diabetes with metformin or lifestyle intervention
2002DPP foundational pre-diabetes RCT
Barzilai et al., 2016 — Cell Metabolism: Metformin as a tool to target aging
2016TAME-rationale paper
Konopka et al., 2019 — Aging Cell: Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults
2019the exercise-blunting RCT
Walton et al., 2019 — Aging Cell: Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults
2019confirms in resistance training
Madiraju et al., 2014 — Nature: Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
2014alternative mGPDH mechanism
Examine.com — Metformin
neutral evidence summary
TAME Trial registry (ClinicalTrials.gov)
Targeting Aging with Metformin